One 2021 study 6 looked at 2,000 adults who were living with overweight or obesity
This report provides a realistic, fact-based explanation without overstating claims or promoting non-approved uses." What the 2026 Report Reveals About AOD-9604 As explained in the new analysis, AOD-9604 is a lipolytic fragment and modified peptide derived from the C-terminus of human growth hormone (HGH), originally developed to explore mechanisms related to fat metabolism, lipolysis, and how the body may burn fat or influence fat cells without affecting growth hormone levels
2.6 Data analyses Dose-response data were fitted to a sigmoidal curve using GraphPad 9.0 (GraphPad, San Diego, CA)
On April 1, 2026, the FDA approved orforglipron (Foundayo) by Eli Lilly for adults with obesity or overweight who also have weight-related medical problems to reduce excess body weight and maintain weight reduction long term, alongside a reduced-calorie diet and increased physical activity
GHK-Cu Research FAQs What is GHK-Cu
While it can still be effective, it is prescribed along with changes to diet and exercise to improve your overall health
